- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.12. | BiomX Inc: BiomX Announces Discontinuation of Phase 2b BX004 Trial Following Internal Review | 125 | GlobeNewswire (Europe) | Following internal analysis and Data Monitoring Committee (DMC) feedback, the Company has elected to discontinue the BX004 Cystic Fibrosis (CF) Phase 2b trial BiomX continues to see potential in... ► Artikel lesen | |
| 08.12. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.11. | H.C. Wainwright reiterates Buy rating on BiomX stock amid FDA queries | 10 | Investing.com | ||
| 28.11. | BiomX: H.C. Wainwright bestätigt Kaufempfehlung trotz FDA-Rückfragen zum Inhalator | 5 | Investing.com Deutsch | ||
| 26.11. | BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review | 8 | Benzinga.com | ||
| 26.11. | BiomX To Continue Cystic Fibrosis Study With Revised Dosing Of BX004; Data Expected In Q2, 2026 | 1 | RTTNews | ||
| 25.11. | BiomX Inc: BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis | 188 | GlobeNewswire (Europe) | The Company continues working with the third-party manufacturer to address recent FDA follow-up information requests which are required to lift the clinical hold concerning the nebulizer device used... ► Artikel lesen | |
| 25.11. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 14.11. | BiomX to implement 1-for-19 reverse stock split on November 25 | 1 | Investing.com | ||
| 14.11. | BiomX announces 1-for-19 reverse stock split | 4 | Seeking Alpha | ||
| 14.11. | BiomX Inc. Announces 1-for-19 Reverse Stock Split | 165 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| 12.11. | BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections | 2 | Seeking Alpha | ||
| 12.11. | BiomX GAAP EPS of $0.29 | 2 | Seeking Alpha | ||
| 12.11. | BiomX Inc: BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates | 323 | GlobeNewswire (Europe) | Positive FDA feedback confirms clear clinical pathway for BX011 targeting S. aureus in Diabetic Foot Infections, building on Company's prior Phase 2 success BiomX expects FDA feedback on BX004 clinical... ► Artikel lesen | |
| 12.11. | BiomX Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11. | Earnings Preview For BiomX | 2 | Benzinga.com | ||
| 04.11. | BiomX Inc: BiomX Announces Positive FDA Feedback Supporting Next-Generation Phage Cocktail Program for Diabetic Foot Infections | 163 | GlobeNewswire (Europe) | NESS ZIONA, Israel, Nov. 04, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting... ► Artikel lesen | |
| 17.10. | BiomX Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.10. | BiomX addresses FDA queries on nebulizer for CF treatment | 4 | Investing.com | ||
| 17.10. | BiomX reagiert auf FDA-Anfragen zu Vernebler für Mukoviszidose-Therapie | 8 | Investing.com Deutsch |
1 2 3 Weiter >>
43 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,95 | +0,19 % | Rheinmetall Aktie: Sehr spannend! - BioNTech, Evotec, Klöckner, PNE und Stabilus im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| AMGEN | 276,75 | -0,04 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,950 | +0,52 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights | Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review
Expect... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,499 | +0,81 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,748 | -3,36 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,893 | +2,29 % | Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions | Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with... ► Artikel lesen | |
| REDHILL BIOPHARMA | 1,190 | 0,00 % | RedHill Biopharma Ltd.: RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells | Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as... ► Artikel lesen | |
| FIBROGEN | 8,600 | 0,00 % | FibroGen, Inc.: Roxadustat Granted Orphan Drug Designation for the Treatment of Myelodysplastic Syndromes by the U.S. Food and Drug Administration | Company is on track to file the Phase 3 protocol in the fourth quarter of 2025 SAN FRANCISCO, Dec. 15, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that the Office of Orphan... ► Artikel lesen | |
| LEXAGENE | - | - | SOLARIA ENERGIA Y MEDIOAMBIENTE, S.A.: Solaria reports it has signed an agreement with Stoneshield Capital to create a new joint venture, Gravyx, specialising in standalone batteries. | ||
| ARMATA PHARMACEUTICALS | 5,100 | -0,97 % | Armata Pharmaceuticals, Inc.: Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update | LOS ANGELES, Nov. 12, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company... ► Artikel lesen | |
| VAXCYTE | 37,000 | -2,12 % | Vaxcyte, Inc. (PCVX) Makes Strides on Pneumonia Treatment, Plots Coverage Extension | ||
| VERRICA PHARMACEUTICALS | 7,100 | +10,08 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results | - Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue - - Reports positive feedback from the FDA... ► Artikel lesen | |
| HOOKIPA PHARMA | 0,870 | +3,55 % | HOOKIPA Pharma Inc.: HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead | NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, "HOOKIPA") today announced the completion of the sale of its assets related to HOOKIPA's HB-400 program and... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 5,770 | 0,00 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome | The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic... ► Artikel lesen | |
| IMMUNOME | 22,640 | 0,00 % | Why Immunome Stock Surged Today |
Das Unternehmen BIOMX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.